Gavin Kluck's questions to Crinetics Pharmaceuticals Inc (CRNX) leadership • Q2 2025
Question
An analyst on behalf of Gavin Kluck from Evercore ISI asked if the early 2026 data readout for Cohort 4 of the adult Phase II CAH study would also include an update on data from the open-label extension (OLE).
Answer
Founder and CEO R. Scott Struthers confirmed that the company plans to provide a broader update on the entire adamelin program at that time. This will include not only Cohort 4 and OLE data but also updates on the ramp-up of the adult and pediatric CAH studies and clarity on the Cushing's disease program.